CRL Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 5.53% compared to Charles River Laboratories International, Inc.'s net margin of 21.47%. Charles River Laboratories International, Inc.'s return on equity of -2.28% beat Johnson & Johnson's return on equity of 33.27%.

Charles River Laboratories International, Inc. has a consensus price target of $197.33, signalling downside risk potential of -1.08%. On the other hand Johnson & Johnson has an analysts' consensus of $210.13 which suggests that it could grow by 1.54%. Given that Johnson & Johnson has higher upside potential than Charles River Laboratories International, Inc., analysts believe Johnson & Johnson is more attractive than Charles River Laboratories International, Inc..

Charles River Laboratories International, Inc. has a beta of 1.613, which suggesting that the stock is 61.299% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.341, suggesting its less volatile than the S&P 500 by 65.861%.

Charles River Laboratories International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.48% to investors and pays a quarterly dividend of $1.30 per share. Charles River Laboratories International, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Charles River Laboratories International, Inc. quarterly revenues are $1B, which are smaller than Johnson & Johnson quarterly revenues of $24B. Charles River Laboratories International, Inc.'s net income of $55.6M is lower than Johnson & Johnson's net income of $5.2B. Notably, Charles River Laboratories International, Inc.'s price-to-earnings ratio is 913.13x while Johnson & Johnson's PE ratio is 19.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International, Inc. is 2.49x versus 5.45x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 5.53% compared to Charles River Laboratories International, Inc.'s net margin of 31.72%. Charles River Laboratories International, Inc.'s return on equity of -2.28% beat Eli Lilly & Co.'s return on equity of 106.26%.

Charles River Laboratories International, Inc. has a consensus price target of $197.33, signalling downside risk potential of -1.08%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 1.73%. Given that Eli Lilly & Co. has higher upside potential than Charles River Laboratories International, Inc., analysts believe Eli Lilly & Co. is more attractive than Charles River Laboratories International, Inc..

Charles River Laboratories International, Inc. has a beta of 1.613, which suggesting that the stock is 61.299% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Charles River Laboratories International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Charles River Laboratories International, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Charles River Laboratories International, Inc. quarterly revenues are $1B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Charles River Laboratories International, Inc.'s net income of $55.6M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Charles River Laboratories International, Inc.'s price-to-earnings ratio is 913.13x while Eli Lilly & Co.'s PE ratio is 53.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International, Inc. is 2.49x versus 16.49x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Medpace Holdings, Inc. has a net margin of 5.53% compared to Charles River Laboratories International, Inc.'s net margin of 16.84%. Charles River Laboratories International, Inc.'s return on equity of -2.28% beat Medpace Holdings, Inc.'s return on equity of 78.26%.

Charles River Laboratories International, Inc. has a consensus price target of $197.33, signalling downside risk potential of -1.08%. On the other hand Medpace Holdings, Inc. has an analysts' consensus of $541.92 which suggests that it could fall by -3.51%. Given that Medpace Holdings, Inc. has more downside risk than Charles River Laboratories International, Inc., analysts believe Charles River Laboratories International, Inc. is more attractive than Medpace Holdings, Inc..

Charles River Laboratories International, Inc. has a beta of 1.613, which suggesting that the stock is 61.299% more volatile than S&P 500. In comparison Medpace Holdings, Inc. has a beta of 1.431, suggesting its more volatile than the S&P 500 by 43.061%.

Charles River Laboratories International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medpace Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Charles River Laboratories International, Inc. pays -- of its earnings as a dividend. Medpace Holdings, Inc. pays out -- of its earnings as a dividend.

Charles River Laboratories International, Inc. quarterly revenues are $1B, which are larger than Medpace Holdings, Inc. quarterly revenues of $659.9M. Charles River Laboratories International, Inc.'s net income of $55.6M is lower than Medpace Holdings, Inc.'s net income of $111.1M. Notably, Charles River Laboratories International, Inc.'s price-to-earnings ratio is 913.13x while Medpace Holdings, Inc.'s PE ratio is 39.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International, Inc. is 2.49x versus 7.21x for Medpace Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Thermo Fisher Scientific, Inc. has a net margin of 5.53% compared to Charles River Laboratories International, Inc.'s net margin of 14.58%. Charles River Laboratories International, Inc.'s return on equity of -2.28% beat Thermo Fisher Scientific, Inc.'s return on equity of 13.15%.

Charles River Laboratories International, Inc. has a consensus price target of $197.33, signalling downside risk potential of -1.08%. On the other hand Thermo Fisher Scientific, Inc. has an analysts' consensus of $639.39 which suggests that it could grow by 10.35%. Given that Thermo Fisher Scientific, Inc. has higher upside potential than Charles River Laboratories International, Inc., analysts believe Thermo Fisher Scientific, Inc. is more attractive than Charles River Laboratories International, Inc..

Charles River Laboratories International, Inc. has a beta of 1.613, which suggesting that the stock is 61.299% more volatile than S&P 500. In comparison Thermo Fisher Scientific, Inc. has a beta of 0.907, suggesting its less volatile than the S&P 500 by 9.346%.

Charles River Laboratories International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Thermo Fisher Scientific, Inc. offers a yield of 0.3% to investors and pays a quarterly dividend of $0.43 per share. Charles River Laboratories International, Inc. pays -- of its earnings as a dividend. Thermo Fisher Scientific, Inc. pays out 9.43% of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Charles River Laboratories International, Inc. quarterly revenues are $1B, which are smaller than Thermo Fisher Scientific, Inc. quarterly revenues of $11.1B. Charles River Laboratories International, Inc.'s net income of $55.6M is lower than Thermo Fisher Scientific, Inc.'s net income of $1.6B. Notably, Charles River Laboratories International, Inc.'s price-to-earnings ratio is 913.13x while Thermo Fisher Scientific, Inc.'s PE ratio is 33.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International, Inc. is 2.49x versus 5.03x for Thermo Fisher Scientific, Inc.. Usually stocks with elevated PS ratios are considered overvalued.